(Reuters) – U.S. drug developer Verastem Inc said on Wednesday its drug to treat some kinds of blood cancer fulfilled the major target in a late-stage research by prolonging the time patients lived with no disease worsening.
When tested on patients suffering from cancers that affect cells of the immune system duvelisib, Verastem’s drug, revealed a survival rate than the current standard of care, Novartis’s Arzerra, Verastem said.
Published at Wed, 06 Sep 2017 11:05:31 +0000
Verastem said it would file in the first half of 2018 for a marketing application for duvelisib.
There’ll be about 62,000 new cases of leukemia in the United States this year, of.
Last year Verastem licensed duvelisib from Infinity Pharmaceuticals Inc.
Reporting by Tamara Mathias in Bengaluru; Editing by Savio D’Souza
The goal was also met by Duvelisib in a trial testing the drug as a treatment for indolent non-Hodgkin’s lymphoma, a slow-progressing cancer of the blood cells, the company said.
The oral drug was tested in 319 patients suffering from chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who did not respond to initial treatment or whose cancer had relapsed.